Alexion Pharmaceuticals, Inc.
Dr. Leonard Bell, CEO
Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and lack effective treatment options. Our first commercial product, Soliris® (eculizumab), is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Alexion is evaluating other potential indications for Soliris and is developing additional highly innovative biotechnology product candidates, which are being investigated across nine other severe and ultra-rare disorders.
Bio-Med Devices, Inc.
Dean Bennett, III, President
Bio-Med Devices, a privately held, ISO registered company, designs, manufactures and markets a complete line of respiratory products for the critical care and transport market. This includes ventilators, air oxygen blenders, breathing circuits, and neonatal resuscitation modules for several large OEM companies. Our products are CE marked and marketed worldwide through dealers in over 90 countries.
Metrum Research Group, LLC
Marc Gastonguay, President & CEO
Metrum Research Group (est. 2004) is a global leader in biomedical modeling and simulation. Metrum Research Group scientists apply quantitative expertise and proprietary disease model libraries to support decisions in biomedical R&D programs for pharmaceuticals, biologic therapeutics, diagnostics, and medical devices. Applications range across all therapeutic areas, with particular emphasis in Alzheimer's Disease, bone health, hepatitis-C, multiple sclerosis, pain, pediatrics and rare disorders. Metrum Research Group is an Inc. 5000 company and has been a Marcum Tech Top 40 winnerfor the past four years.